Preventing liver cancer: Assessing the benefits of risk assessment for patients with metabolic-associated fatty liver disease
-
Preventing liver cancer: Assessing the benefits of risk assessment for patients with metabolic-associated fatty liver disease
Resource category:
Reports Link opens in a new window
-
Assessing the benefits and costs of risk-stratified surveillance for patients with metabolic-associated fatty liver disease
Preventing liver cancer infographic
Link opens in a new window -
Modelling estimates for diagnosis and surveillance of MASH and MAFLD patients
Preventing liver cancer supplementary report
Link opens in a new window -
Scoping review on diagnostic technologies for the diagnosis of MASH in MAFLD patients
Preventing liver cancer supplementary report
Link opens in a new window -
Scoping review on disease prevalence and transitions for MAFLD/MASH patients
Preventing liver cancer supplementary report
Link opens in a new window
Reports 
The project identified the health benefits and cost-effectiveness of routine hepatocellular carcinoma (HCC) surveillance for metabolic-associated steatohepatitis (MASH) patients in Australia and assessed the recent evidence available of disease prevalence and transitions for metabolic-associated fatty liver disease (MAFLD) and MASH patients, and diagnostic technologies for the diagnosis of MASH in MAFLD patients.
Associated content
-
Preventing liver cancer: obesity and alcohol consumption
Resource category:
Reports
Date -
Infographic: Assessing the benefits and costs of risk-stratified surveillance for patients with metabolic-associated fatty liver disease
Resource category:
Visuals
Date -
Seminar: Building an economic case and planning for liver cancer control
Resource category:
Videos
Date -
Successful seed funding grants announced
News Category: Prevention Centre NewsDate
Visuals 
Videos 
Findings Brief